Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by TeddyTenBagson May 27, 2021 11:14pm
194 Views
Post# 33284036

RE:RE:RE:RE:RE:Squeeze

RE:RE:RE:RE:RE:SqueezeActually, I don't think YOU understand. Short volume means nothing. Short interest is what matters. Short interest represents the number of shorted shares that have yet to be closed out or covered by investors. That, as a % of total share count is peanuts at this point for MindMed. If and when that grows and the stock has a heavy short interest is when you could possibly run the risk of a short squeeze. 

Get an education, stop trying to mislead people because you're a bag holder and keep liking your own posts.

Superss63 wrote:

Yeah okay, you believe what you want to believe  

The amount of outstanding shares mean SFA, it's the average daily  shares traded that matter to the shorts. But you don't seem to understand. 

25 May % of Vol shorted 57.98 

L



<< Previous
Bullboard Posts
Next >>